David B. Agus, MD

David-Agus-Phil-Channing

David B. Agus, MD

Professor of Medicine and Engineering
Founding Director
Chief Executive Officer

+1 310 272 7640
agus@usc.edu

Dr. David B. Agus is a Professor of Medicine and Engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and Chief Executive Officer of the Lawrence J. Ellison Institute for Transformative Medicine of USC. Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs and directs a National Cancer Institute Physical Sciences in Oncology Center at USC. He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called The End of Illness was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books A Short Guide to a Long Life and The Lucky Years: How to Thrive in the Brave New World of Health are also New York Times and international best sellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.


Education

BA

1987 Molecular Biology – Princeton University, Princeton, NJ

MD

1992 Medicine – University of Pennsylvania School of Medicine, Philadelphia, PA

Internship

1992-1993 – John Hopkins Hospital (Osler Intern in International Medicine), Baltimore, MD

Residency

1993-1994 – John Hopkins Hospital (Osler Resident in Internal Medicine), Baltimore, MD

Fellowship

1994-1997 – Cornell University Medical Center (Fellow-Medicine), Ithica, NY
1994-1996 – Memorial Sloan-Kettering Cancer Center (Fellow-Medical Oncology), New York, NY
1996-1997 – Memorial Sloan-Kettering Cancer Center (Special Fellow-Medical Oncology), New York, NY


Research Focus

  • Molecular Targeted Therapy of Cancer
  • Proteomics
  • Personalized Medicine
  • Physical Sciences in Oncology

Awards

  • USC Association of Trojan Leagues Outstanding Service Annual Award, 2013
  • Healthspottr, Future Health 100 leaders in healthcare #26, 2012-2013
  • British Medical Association Commendation, Popular Medicine Book, 2012
  • Biotech Humanitarian Award:Selected Judge, 2009
  • Geoffrey Beene Foundation/GQ Magazine Rock Star of Science AwardTM, 2009
  • HealthNetwork Foundation Excellence Award, 2008
  • CaP CURE Young Investigator Award, 1998-2001
  • Clinical Scholar of the Sloan-Kettering Institute, 1996
  • American Cancer Society Clinical Oncology Fellowship Award, 1994

Publications

Agus DB, Gaudette É, Goldman DP, Messali A. The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016 Nov 30;11(11):e0166103 View in: PubMed

Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 Oct 6;6:34785. View in: PubMed

Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21;10(1):92. View in: PubMed

Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 Jul 25;6:29752. View in: PubMed

Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, Agus DB, Blume JE. A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016 Jun; 15(2):186-194. e13. View in: PubMed

Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus DB, Fraser SE, Ruderman D. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016; 6:22435. View in: PubMed

Agus DB. The Doctor Will See You (and Your Data) Now. Fortune. 2016 Jan 1; 173(1):90-3. View in: Fortune.com

Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. View in: PubMed

Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. View in: PubMed

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 1; 33(7):723-31. View in: PubMed

Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. View in: PubMed

Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Dreicer R, Maclean D, Suri A, Stadler WM, Shevrin D, Hart L, Macvicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II Trial of Orteronel (TAK-700)–an Investigational 17,20-Lyase Inhibitor–in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2014 Mar 1; 20(5):1335-44. View in: PubMed

Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. View in: PubMed

Taylor-Ford M, Meyerowitz BE, D’Orazio LM, Christie KM, Gross ME, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. View in: PubMed

Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells.
Sci Rep. 2013; 3:1449. View in: PubMed

Agus DB, Gell-Mann M. Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. View in: PubMed

Agus DB. Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. View in: PubMed

Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, Maccoss M, Tabb DL, Mallick P. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct 10; 30(10):918-20. View in: PubMed

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. View in: PubMed

Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M. Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. View in: PubMed

Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. View in: PubMed

Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. View in: PubMed

Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. View in: PubMed

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. View in: PubMed

Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. View in: PubMed

Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. View in: PubMed

Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 1; 70(5):1989-99. View in: PubMed

Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus DB, Cristini V. Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. View in: PubMed

Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. View in: PubMed

Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 1; 24(21):2534-6. View in: PubMed

Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. View in: PubMed

Stephan D, Agus D, Nierenberg M, Silver E. Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. View in: PubMed

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1; 68(6):629-39. View in: PubMed

Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 1; 13(7):1979-86. View in: PubMed

Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. View in: PubMed

Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. View in: PubMed

Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007; 7:142. View in: PubMed

deVera IE, Katz JE, Agus DB. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. View in: PubMed

Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. View in: PubMed

Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006 Jan 16; 94(1):85-92. View in: PubMed

Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. View in: PubMed

Katz JE, Mallick P, Agus DB. A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. View in: PubMed

Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. View in: PubMed

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. View in: PubMed

Jain A, Agus DB. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. View in: PubMed

Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 1; 61(3):228-35. View in: PubMed

Shazer RL, Luthringer D, Agus DB, Gross ME. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. View in: PubMed

Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. View in: PubMed

Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1; 22(3):537-56. View in: PubMed

Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. View in: PubMed

Gross ME, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. View in: PubMed

Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. View in: PubMed

Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 6; 94(21):1641-7. View in: PubMed

Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. View in: PubMed

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. View in: PubMed

Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. View in: PubMed

Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. View in: PubMed

Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. View in: PubMed

Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11720-4. View in: PubMed

Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001 Sep; 7(9):2643-7. View in: PubMed

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr; 7(4):962-70. View in: PubMed

Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. View in: PubMed

Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX. A potential role for activated HER-2 in prostate cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):76-83; discussion 92-100. View in: PubMed

Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000 Nov 1; 60(21):6134-41. View in: PubMed

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000 Sep 15; 60(18):5165-70. View in: PubMed

McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000 May 1; 60(9):2317-22. View in: PubMed

Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999 Dec; 17(12):3776-85. View in: PubMed

Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999 Nov 3; 91(21):1869-76. View in: PubMed

Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999 Oct 1; 59(19):4761-4. View in: PubMed

Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999 Sep 15; 59(18):4555-8. View in: PubMed

Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998 Jul 15; 58(14):3009-14. View in: PubMed

Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN. Workgroup 2: human xenograft models of prostate cancer. Prostate. 1998 Jun 15; 36(1):56-8. View in: PubMed

Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 Dec 1; 100(11):2842-8. View in: PubMed

Sprent J, Surh CD, Agus D, Hurd M, Sutton S, Heath WR. Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J Exp Med. 1994 Jul 1; 180(1):307-17. View in: PubMed

Deguchi Y, Agus D, Kehrl JH. A human homeobox gene, HB24, inhibits development of CD4+ T cells and impairs thymic involution in transgenic mice. J Biol Chem. 1993 Feb 15; 268(5):3646-53. View in: PubMed

Agus DB, Surh CD, Sprent J. Reentry of T cells to the adult thymus is restricted to activated T cells. J Exp Med. 1991 May 1; 173(5):1039-46. View in: PubMed

Agus D, Mann R, Clayman M, Kelly C, Michaud L, Cohn D, Neilson EG. The effects of daily cyclophosphamide administration on the development and extent of primary experimental interstitial nephritis in rats. Kidney Int. 1986 Mar; 29(3):635-40. View in: PubMed

Agus D, Mann R, Cohn D, Michaud L, Kelly C, Clayman M, Neilson EG. Inhibitory role of dietary protein restriction on the development and expression of immune-mediated antitubular basement membrane-induced tubulointerstitial nephritis in rats. J Clin Invest. 1985 Sep; 76(3):930-6. View in: PubMed